Evidence map›Paper›PMID 35549877›Full record

ArticleCurrent topics in medicinal chemistry2022

Radiopharmacokinetics of Graphene Quantum Dots Nanoparticles

Matheus Keuper Bastos, Martha Sahylí Ortega Pijeira, Juliana Helena de Souza Sobrinho, Ana Paula Dos Santos Matos, Eduardo Ricci-Junior, Pierre Basilio de Almeida Fechine, Luciana Magalhães Rebelo Alencar, Sara Gemini-Piperni, Frank Alexis, Mohamed Fathy Attia and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Current topics in medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Matheus Keuper BastosBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmaceuticals and Synthesis of Novel Radiopharmaceuticals, Rio de Janeiro 21941906, Brazil.
Martha Sahylí Ortega PijeiraBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmaceuticals and Synthesis of Novel Radiopharmaceuticals, Rio de Janeiro 21941906, Brazil.
Juliana Helena de Souza SobrinhoLaboratory of Biosystems, Grande Rio University, Rio de Janeiro, 25071-202, Brazil.
Ana Paula Dos Santos MatosSchool of Pharmacy, Galenic Development Laboratory (LADEG), Federal University of Rio de Janeiro, Rio de Janeiro, 21941-170, Brazil.
Eduardo Ricci-JuniorSchool of Pharmacy, Galenic Development Laboratory (LADEG), Federal University of Rio de Janeiro, Rio de Janeiro, 21941-170, Brazil.
Pierre Basilio de Almeida FechineGroup of Chemistry of Advanced Materials (GQMat)- Department of Analytical Chemistry and Physical-Chemistry, Federal University of Ceará, Fortaleza-CE, 451-970, Brazil.
Luciana Magalhães Rebelo AlencarDepartment of Physics, Laboratory of Biophysics and Nanosystems, Federal University of Maranhão, Campus Bacanga, São Luís, Maranhão, 65080-805, Brazil.
Sara Gemini-PiperniInstitute of Biological Sciences (ICB), Federal University of Rio de Janeiro, Rio de Janeiro, 21940000 Brazil.
Frank AlexisPolitécnico, Quito 170910, Ecuador, Universidad San Francisco de Quito USFQ.
Mohamed Fathy AttiaCenter for Nanotechnology in Drug Delivery and Division of Pharmaco-engineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Ralph Santos-OliveiraBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmaceuticals and Synthesis of Novel Radiopharmaceuticals, Rio de Janeiro 21941906, Brazil.

Funding

Carlos Chagas Filho Foundation for Research Support of Rio de Janeiro State (FAPERJ) E-26/200.815/2021, E-26/010.000981/2019, E-26/010.002362/2019, E-26/211.269/2021, E-26//211.207/2021, E-26/202.320/2021CNPq, Conselho Nacional de Desenvolvimento Científico e Tecnológico 301069/2018-2
6 · The paper itself

Abstract

backgroundNanoparticles (NPs) have gained great importance during the last decades for developing new therapeutics with improved outcomes for biomedical applications due to their nanoscale size, surface properties, loading capacity, controlled drug release, and distribution. Among the carbon-based nanomaterials, one of the most biocompatible forms of graphene is graphene quantum dots (GQDs). GQDs are obtained by converting 2D graphene into zero-dimensional graphene nanosheets. Moreover, very few reports in the literature reported the pharmacokinetic studies proving the safety and effectiveness of GQDs for in vivo applications.

objectivesThis study evaluated the pharmacokinetics of GQDs radiolabeled with

methodsThe graphene quantum dots were produced and characterized by RX diffractometry, Raman spectroscopy, and atomic force microscopy. The pharmacokinetic analysis was performed following the radiopharmacokinetics concepts, using radiolabeled graphene quantum dots with technetium 99 metastable (99mTc). The radiolabeling process of the graphene quantum dots with 99mTc was performed by the direct via.

resultsThe results indicate that the pharmacokinetic analyses with GQDs over a longer period were more accurate. Following a bicompartmental model, the long-time analysis considers each pharmacokinetic phase of drugs into the body. Furthermore, the data demonstrated that short-time analysis could lead to distortions in pharmacokinetic parameters, leading to misinterpretations.

conclusionThe evaluation of the pharmacokinetics of GQDs over long periods is more meaningful than the evaluation over short periods.

Indexed as

GraphiteNanoparticlesNanostructuresQuantum DotsAnimalsRatsRats, WistarGraphite99mTc labelingGQDs.Graphene quantum dotsIn vivo analysesNanoparticlesPharmacokinetics

Identifiers

PMID35549877

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.